Regimed Medical

St. Peters, MO

UEI
M2AHN6XHZFZ5
CAGE
0VAA7
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

FY2025 rankings
Self-certified in SAM.gov
  • Minority Owned Business
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • DOT Certified DBE
  • Black American Owned
Entity structure
Sole Proprietorship
SAM.gov registration date
Physical address
106 Arabian Path, St Peters, MO 63376, USA
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
51 Wholesale Trade – Nondurable Goods
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $495,100
FY2025 $548,858
FY2024 $2,285,657
FY2023 $2,133,301

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of Veterans Affairs $495,100

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

About the company

Regimed Medical, a minority-owned, Black American-owned small disadvantaged business based in St. Peters, Missouri, supplies pharmaceutical products and medical devices to federal healthcare agencies as a prime contractor exclusively, holding a $6.34 million single-award Indefinite Delivery Contract with the National Cancer Institute and receiving recurring purchase orders across the Veterans Affairs network. The sole proprietorship competes predominantly under total small business set-asides, with 146 of 176 recent awards (83%) classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 144 awards (82%) under PSC 6505 (Drugs and Biologicals).

Regimed Medical's customer concentration is heavily skewed toward the Department of Veterans Affairs, which accounts for 77% of recent awards by count. Within VA, Veterans Integrated Service Network 15 dominates with 56 awards valued at $2.1 million combined potential value, followed by VISN 7 with 34 awards ($440 thousand), VISN 1 with 19 awards ($349 thousand), and VISN 12 with 15 awards ($1.1 million). However, the dollar rankings shift substantially when the National Cancer Institute enters the picture: the NCI alone anchors 89% of combined potential value across the portfolio at $10.2 million, driven by the $6.34 million IDIQ awarded March 27, 2023. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response adds $4.2 million in potential value on a single award. This dual-customer structure—many small VA purchase orders for routine pharmaceuticals alongside a large, long-term NCI vehicle—creates two distinct revenue streams with very different recompete dynamics.

Regimed Medical holds a single named parent vehicle: the NCI Indefinite Delivery Contract 75N91023D00005, valued at $6.34 million with ultimate completion March 26, 2027. Five delivery orders have been placed under this IDIQ since award, ranging from $219 thousand to $1.7 million, for nilotinib tablets and capsules in 150 mg and 200 mg strengths supporting the NCI's Cancer Therapy Evaluation Program. The most recent delivery order, a $219,850 award for TASIGNA capsules, was issued July 10, 2025, with performance at Frederick, Maryland and completion targeted July 9, 2026. All other awards are individual purchase orders issued directly by VA Consolidated Mail Outpatient Pharmacy facilities and the Office of the Assistant Secretary for Preparedness and Response, with typical order values ranging from $14 thousand to $489 thousand and firm fixed-price terms. Representative VA work includes a $292,931 purchase order from VISN 22 (July 2026) for drospirenone 4 mg tablets to the Tucson CMOP facility, a $139,996 order from VISN 15 (April 2026) for hydrocortisone acetate suppositories across seven CMOP facilities, and a $1.7 million delivery order from the NCI (November 2023) for nilotinib tablets in support of cancer research.

Activity has declined in recent years—from nine awards in 2022 to five in 2026 year-to-date—with only one award scheduled for recompete within the next twenty-four months ($48 thousand combined potential value). The portfolio reflects episodic, demand-driven pharmaceutical purchasing across nineteen distinct federal agencies rather than a consolidated procurement strategy. Regimed Medical operates exclusively as a prime contractor with no subcontract footprint, and maintains no positions on government-wide acquisition contracts or multiple-award vehicles beyond the NCI IDIQ. The vendor's federal posture is entirely small-business set-aside driven on the VA side, with the NCI work marked as unrestricted competition.

SBA capabilities narrative

DISTRIBUTE MEDICAL & LABORATORY SUPPLIES & EQUIPMENT. ALL HOSPITAL & MEDICAL NEEDS FOR DISPOSABLE & NONDISPOSABLE ITEMS. DISTRIBUTE ALL PHARMACEUTICAL SUPPLIES

Quick answers

Is Regimed Medical registered in SAM.gov?

Yes. Regimed Medical's SAM.gov registration is active through March 1, 2027.

How much has Regimed Medical received in federal contracts?

Federal contracts obligated $548,858 to Regimed Medical in fiscal year 2025 and $5,462,916 in fiscal years 2023 through 2027.

How does Regimed Medical rank among federal contractors?

Regimed Medical ranked #76 in NAICS 325413 in FY2025.

What is Regimed Medical's most recent federal award?

Regimed Medical's most recent federal contract award is EO 14398 candesartan cilexetil 4MG tab 90CT (36C77026P0123), from Veterans Integrated Service Network 15 (VHA), on August 10, 2026.

On GovTribe

See Regimed Medical's full federal record

  • Federal contract awards
  • IDV awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors